Evidence map›Paper›PMID 34439239›Full record

ArticleCancers2021

A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study.

Yun Li, Jin Ji, Ji Lyu, Xin Jin, Xing He, Shaojia Mo, Huan Xu, Jingyi He, Zhi Cao, Xi Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. The diagnostic role and mechanistic functions of exosomal lncRNAs in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  17. Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yun LiDepartment of Urology, Shanghai Shibei Hospital of Jingan District, Shanghai 200435, China.
Jin JiDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Ji LyuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Xin JinDepartment of Urology, Zhongda Hospital, Southeast University, Nanjing 210044, China.
Xing HeDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Shaojia MoSchool of Basic Medicine, Second Military Medical University, Shanghai 200433, China.
Huan XuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Jingyi HeDepartment of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Zhi CaoDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Xi ChenDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Yalong XuDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Lei WangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Fubo WangDepartment of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed at developing and validating a novel noninvasive urinary exosome-based post-DRE (digital rectal examination) lncRNA assay to diagnose PCa (prostate cancer) and clinically significant PCa (Gleason score ≥ 7) from the initial prostate biopsy.

methodsA total of 602 urine samples from eligible participants were collected. The expression levels of urinary exosomal PCA3 (prostate cancer antigen 3) and MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) were detected by qPCR (quantitative real-time PCR). Receiver operating characteristic (ROC) analysis was applied to evaluate the diagnostic performance of PCA3, MALAT1 and the lncRNA assay. A decision curve analysis (DCA) and waterfall plots were used to assess the clinical value of the lncRNA assay.

resultsUrinary exosomal PCA3 and MALAT1 were overexpressed in PCa and clinically significant PCa (

conclusionWe developed and validated a novel noninvasive post-DRE urine-based lncRNA assay that presented good diagnostic power and clinical utility for the early diagnosis of PCa and high-grade PCa.

Indexed as

diagnosisexosomeslncRNA assayMALAT1PCA3prostate cancer

Identifiers

PMID34439239
PMCPMC8393262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.